- Home
- ALLR vs SONN Comparison
ALLR vs SONN Comparison
Compare ALLR & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- SONN
- Stock Information
- Founded
- ALLR 2004
- SONN N/A
- Country
- ALLR United States
- SONN United States
- Employees
- ALLR N/A
- SONN N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- SONN Health Care
- Exchange
- ALLR Nasdaq
- SONN Nasdaq
- Market Cap
- ALLR 21.8M
- SONN 21.4M
- IPO Year
- ALLR N/A
- SONN N/A
- Fundamental
- Price
- ALLR $1.42
- SONN $4.51
- Analyst Decision
- ALLR Strong Buy
- SONN Strong Buy
- Analyst Count
- ALLR 1
- SONN 1
- Target Price
- ALLR $9.25
- SONN $20.00
- AVG Volume (30 Days)
- ALLR 327.2K
- SONN 468.3K
- Earning Date
- ALLR 11-13-2025
- SONN 08-13-2025
- Dividend Yield
- ALLR N/A
- SONN N/A
- EPS Growth
- ALLR N/A
- SONN N/A
- EPS
- ALLR N/A
- SONN N/A
- Revenue
- ALLR N/A
- SONN $1,000,000.00
- Revenue This Year
- ALLR N/A
- SONN $5,376.22
- Revenue Next Year
- ALLR N/A
- SONN N/A
- P/E Ratio
- ALLR N/A
- SONN N/A
- Revenue Growth
- ALLR N/A
- SONN 1689.52
- 52 Week Low
- ALLR $0.61
- SONN $1.08
- 52 Week High
- ALLR $2.35
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- ALLR 40.01
- SONN 49.41
- Support Level
- ALLR $1.40
- SONN $3.52
- Resistance Level
- ALLR $1.53
- SONN $4.18
- Average True Range (ATR)
- ALLR 0.12
- SONN 0.47
- MACD
- ALLR -0.03
- SONN -0.10
- Stochastic Oscillator
- ALLR 1.49
- SONN 36.90
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.